Skip to main content
Premium Trial:

Request an Annual Quote

LifeCodexx, Charité Partner on Preeclampsia Detection Assay

NEW YORK (GenomeWeb) – LifeCodexx and Charité–University Medicine Berlin announced today that they have partnered to develop an assay for the early detection of preeclampsia.

The planned test will be based on LifeCodexx's methylation-specific quantitative PCR technology, which exploits the different methylation profiles of maternal and fetal DNA found in maternal plasma. The company recently received CE marking for a version of its PrenaTest fetal trisomy 21 assay based on the technology.

LifeCodexx said it has already developed a qPCR assay that can distinguish between patients with and without preeclampsia in collaboration with University Hospital Wuerzburg. By working with Charité, it aims to refine the test to predict preeclampsia at an early stage of pregnancy.

The company expects to launch the new assay "within the coming year," LifeCodexx CEO Michael Lutz said in a statement.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge is weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.